Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice

被引:91
作者
Koedoot, CG
de Haan, RJ
Stiggelbout, AM
Stalmeier, PFM
de Graeff, A
Bakker, PJM
de Haes, JCJM
机构
[1] Acad Med Ctr, Dept Psychol Med, NL-1100 DE Amsterdam, Netherlands
[2] Acad Med Ctr, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands
[3] Leiden Univ, Dept Clin Decis Making, Med Ctr, Leiden, Netherlands
[4] Univ Med Ctr, Dept Internal Med, Utrecht, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
关键词
palliative chemotherapy; best supportive care; decision-making; treatment preference; treatment choice;
D O I
10.1038/sj.bjc.6601445
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In palliative cancer treatment, the choice between palliative chemotherapy and best supportive care may be difficult. In the decision-making process, giving information as well as patients values and preferences become important issues. Patients, however, may have a treatment preference before they even meet their medical oncologist. An insight into the patient's decision-making process can support clinicians having to inform their patients. Patients (n=207) with metastatic cancer, aged 18 years or older, able to speak Dutch, for whom palliative chemotherapy was a treatment option, were eligible for the study. We assessed the following before they consulted their medical oncologist: (1) socio-demographic characteristics, (2) disease-related variables, (3) quality-of-life indices, (4) attitudes and (5) preferences for treatment, information and participation in decision-making. The actual treatment decision, assessed after it had been made, was the main study outcome. Of 207 eligible patients, 140 patients (68%) participated in the study. At baseline, 68% preferred to undergo chemotherapy rather than wait watchfully. Eventually, 78% chose chemotherapy. Treatment preference (odds ratio (OR) = 10.3, confidence interval (CI) 2.8-38.0) and a deferring style of decision-making (OR=4.9, CI 1.4-17.2) best predicted the actual treatment choice. Treatment preference (total explained variance = 38.2%) was predicted, in turn, by patients striving for length of life (29.5%), less striving for quality of life (6.1%) and experienced control over the cause of disease (2.6%). Patients actual treatment choice was most strongly predicted by their preconsultation treatment preference. Since treatment preference is positively explained by striving for length of life, and negatively by striving for quality of life, it is questionable whether the purpose of palliative treatment is made clear. This, paradoxically, emphasises the need for further attention to the process of information giving and shared decision-making.
引用
收藏
页码:2219 / 2226
页数:8
相关论文
共 51 条
[11]   Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer [J].
Doyle, C ;
Crump, M ;
Pintilie, M ;
Oza, AM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1266-1274
[12]  
*DUTCH CANC FDN, 1999, SIGN 1999 DEELR
[13]   The importance of patient preference in the decision to screen for prostate cancer [J].
Flood, AB ;
Wennberg, JE ;
Nease, RF ;
Fowler, FJ ;
Ding, J ;
Hynes, LM .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1996, 11 (06) :342-349
[14]   Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer [J].
Geels, P ;
Eisenhauer, E ;
Bezjak, A ;
Zee, B ;
Day, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2395-2405
[15]   The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types -: Summary and conclusions [J].
Glimelius, B ;
Bergh, J ;
Brandt, L ;
Brorsson, B ;
Gunnars, B ;
Hafström, L ;
Haglund, U ;
Högberg, T ;
Janunger, KG ;
Jönsson, PE ;
Karlsson, G ;
Kimby, E ;
Lamnevik, G ;
Nilsson, S ;
Permert, J ;
Ragnhammar, P ;
Sörenson, S ;
Nygren, P .
ACTA ONCOLOGICA, 2001, 40 (2-3) :135-154
[16]   Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? [J].
Jansen, SJT ;
Kievit, J ;
Nooij, MA ;
de Haes, JCJM ;
Overpelt, IME ;
van Slooten, H ;
Maartense, E ;
Stiggelbout, AM .
BRITISH JOURNAL OF CANCER, 2001, 84 (12) :1577-1585
[17]  
Karnofsky DA., 1949, CLIN EVALUATION CHEM, P196
[18]   CHOICES IN ONCOLOGY - FACTORS THAT INFLUENCE PATIENTS TREATMENT PREFERENCE [J].
KIEBERT, GM ;
STIGGELBOUT, AM ;
KIEVIT, J ;
LEER, JWH ;
VANDEVELDE, CJH ;
DEHAES, HJCJM .
QUALITY OF LIFE RESEARCH, 1994, 3 (03) :175-182
[19]   Palliative chemotherapy or watchful waiting? A vignettes study among oncologists [J].
Koedoot, CG ;
de Haes, JCJM ;
Heisterkamp, SH ;
Bakker, PJM ;
de Graeff, A ;
de Haan, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3658-3664
[20]  
KOEDOOT CG, 1996, PSYCHOL ONCOL, V5, P174